Hospital
Northern Utah Healthcare Corporation
Northern Utah Healthcare Corporation was paid $35.69M by Medicaid between Jan 2018 and Dec 2024, across 240 billing codes. Its largest line is 8888888, Internal/system code - not a standard HCPCS code — 67% of everything it billed.
33Billing provider infoNORTHERN UTAH HEALTHCARE CORPORATION
SALT LAKE CITY, UT 84124
SALT LAKE CITY, UT 84124
33aNPI1164469243assigned 05/31/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$35.69M
24GClaims708,979
24DCodes billed240
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Utah
Rank by total paid#1 of 26
Median peer was paid$6.14M
This provider vs. median5.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 104,598 | $4.58M | |
| 2019 | 134,312 | $5.19M | |
| 2020 | 136,825 | $6.95M | |
| 2021 | 158,778 | $9.06M | |
| 2022 | 150,598 | $8.71M | |
| 2023 | 17,356 | $776K | |
| 2024incomplete | 6,512 | $427K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 8888888 | Internal/system code - not a standard HCPCS code | 67% | 77,913 | 39,100 | $23.77M |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.0% | 16,201 | 13,441 | $2.13M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.1% | 34,176 | 30,539 | $1.47M |
| 80053 | Comprehensive metabolic panel | 3.0% | 37,604 | 30,942 | $1.08M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.7% | 4,651 | 4,173 | $970K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.5% | 39,597 | 33,197 | $898K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.4% | 8,136 | 6,999 | $501K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.0% | 8,753 | 8,102 | $373K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 4,046 | 3,769 | $319K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,026 | 2,803 | $296K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,773 | 6,640 | $208K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 5,843 | 5,097 | $187K |
228 more codes
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,980 | $183K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,994 | $178K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,093 | $166K |
| 81001 | <1% | 23,140 | $163K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,556 | $158K |
| 71045 | Radiologic examination, chest; single view | <1% | 11,553 | $152K |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,518 | $124K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,502 | $121K |
| 87081 | <1% | 2,593 | $120K | |
| 87400 | <1% | 3,334 | $118K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,199 | $96K |
| 73130 | <1% | 1,353 | $95K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,349 | $89K |
| 73610 | <1% | 1,492 | $82K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 22,498 | $78K |
| 99285 | Emergency room visit (most serious) | <1% | 7,321 | $78K |
| 73630 | <1% | 1,634 | $76K | |
| J3490 | Unclassified drugs | <1% | 243 | $73K |
| 73030 | <1% | 1,166 | $58K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 5,573 | $54K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,928 | $52K |
| 85027 | <1% | 47,120 | $48K | |
| 73110 | <1% | 883 | $45K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,595 | $43K |
| 87070 | <1% | 1,008 | $40K | |
| 73564 | <1% | 749 | $39K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,981 | $37K |
| 87210 | <1% | 1,004 | $34K | |
| 10060 | <1% | 497 | $34K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,601 | $34K |
| 84703 | <1% | 11,406 | $33K | |
| 72100 | <1% | 758 | $31K | |
| 84702 | <1% | 1,774 | $29K | |
| 76801 | <1% | 1,314 | $28K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,416 | $27K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,674 | $27K |
| 12001 | <1% | 393 | $25K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,783 | $25K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 260 | $25K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,584 | $24K |
| 87490 | <1% | 1,614 | $22K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,807 | $19K |
| 81025 | <1% | 2,658 | $19K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,400 | $19K |
| 84112 | <1% | 118 | $18K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,983 | $18K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,781 | $18K |
| 87077 | <1% | 865 | $18K | |
| 62323 | <1% | 54 | $16K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 355 | $16K |
| 74018 | <1% | 350 | $15K | |
| 73080 | <1% | 306 | $14K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 15,588 | $14K |
| 84484 | <1% | 11,982 | $12K | |
| 96376 | <1% | 4,231 | $12K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,802 | $12K |
| 70486 | <1% | 405 | $12K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,274 | $11K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 11,384 | $11K |
| 93971 | <1% | 1,061 | $11K | |
| 86850 | <1% | 1,562 | $9K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 293 | $9K |
| 12011 | <1% | 126 | $9K | |
| 72170 | <1% | 319 | $9K | |
| 73590 | <1% | 179 | $8K | |
| 73090 | <1% | 159 | $8K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,057 | $8K |
| 83690 | <1% | 14,725 | $8K | |
| 73562 | <1% | 108 | $7K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 535 | $7K |
| 72131 | <1% | 285 | $7K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 30 | $6K |
| 73502 | <1% | 138 | $6K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,964 | $6K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 152 | $6K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 14,114 | $6K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,550 | $5K |
| 12002 | <1% | 119 | $5K | |
| G0378 | Hospital observation service, per hour | <1% | 2,961 | $5K |
| 87040 | <1% | 3,563 | $5K | |
| 87807 | <1% | 470 | $5K | |
| 93975 | <1% | 1,430 | $4K | |
| 83735 | <1% | 8,648 | $4K | |
| 82550 | <1% | 3,796 | $4K | |
| 82607 | <1% | 175 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,015 | $3K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 86 | $3K |
| 83605 | <1% | 4,739 | $3K | |
| 80076 | <1% | 1,287 | $3K | |
| 85610 | <1% | 6,419 | $3K | |
| 83880 | <1% | 3,681 | $3K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 29 | $3K |
| 85379 | <1% | 3,081 | $3K | |
| 87634 | <1% | 33 | $2K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 13 | $2K |
| 86900 | <1% | 2,255 | $2K | |
| 72141 | <1% | 16 | $2K | |
| 73120 | <1% | 73 | $2K | |
| 87590 | <1% | 1,614 | $2K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 15 | $2K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,884 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,207 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,748 | $2K |
| 87631 | <1% | 56 | $2K | |
| 88304 | <1% | 88 | $2K | |
| 87205 | <1% | 963 | $1K | |
| 80179 | <1% | 3,436 | $1K | |
| 85007 | <1% | 478 | $1K | |
| 73560 | <1% | 13 | $1K | |
| 85014 | <1% | 398 | $1K | |
| 82950 | <1% | 98 | $1K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,221 | $1K |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 27 | $1K |
| 87177 | <1% | 38 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,847 | $1K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 13 | $1K |
| 93017 | <1% | 62 | $1K | |
| 87186 | <1% | 2,296 | $1K | |
| 82274 | <1% | 61 | $959.65 | |
| 82553 | <1% | 284 | $935.69 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,884 | $899.53 |
| 86140 | <1% | 1,297 | $894.53 | |
| 80329 | <1% | 920 | $876.46 | |
| 87340 | <1% | 176 | $844.48 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 497 | $796.29 |
| 85651 | <1% | 1,044 | $748.38 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 646 | $736.18 |
| 82728 | <1% | 50 | $725.79 | |
| 87088 | <1% | 127 | $724.99 | |
| 80143 | <1% | 3,448 | $672.34 | |
| 99152 | <1% | 1,112 | $670.46 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,573 | $617.77 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 115 | $609.41 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,797 | $580.08 |
| 80061 | Lipid panel | <1% | 728 | $564.07 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | <1% | 136 | $554.54 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,177 | $550.94 |
| 88307 | <1% | 59 | $549.47 | |
| 93970 | <1% | 25 | $488.92 | |
| 87147 | <1% | 68 | $470.39 | |
| 29125 | <1% | 29 | $466.56 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 530 | $466.23 |
| 70496 | <1% | 231 | $421.26 | |
| 80320 | <1% | 1,192 | $415.30 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 880 | $405.59 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,706 | $384.86 |
| 90715 | <1% | 804 | $371.51 | |
| 86762 | <1% | 121 | $365.41 | |
| 84439 | <1% | 148 | $306.56 | |
| 82043 | <1% | 26 | $280.59 | |
| 70498 | <1% | 296 | $265.18 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 968 | $252.87 |
| 97163 | <1% | 732 | $249.90 | |
| 85730 | <1% | 3,790 | $246.22 | |
| 86780 | <1% | 157 | $236.14 | |
| 76770 | <1% | 13 | $204.41 | |
| 76642 | <1% | 13 | $188.92 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 47 | $166.92 |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 320 | $163.85 |
| 97032 | <1% | 50 | $156.47 | |
| C1769 | Guide wire | <1% | 517 | $155.62 |
| 84132 | <1% | 240 | $135.35 | |
| 82565 | <1% | 15 | $112.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 289 | $89.30 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,541 | $73.55 |
| 86901 | <1% | 2,254 | $73.36 | |
| 97167 | <1% | 149 | $71.98 | |
| 80164 | <1% | 34 | $69.88 | |
| A9270 | Non-covered item or service | <1% | 4,364 | $69.15 |
| 97116 | <1% | 671 | $57.06 | |
| 86677 | <1% | 13 | $27.86 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,968 | $24.71 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 828 | $21.94 |
| J2704 | Injection, propofol, 10 mg | <1% | 2,423 | $19.33 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,516 | $12.48 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,162 | $10.53 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 473 | $9.64 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 428 | $5.88 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 751 | $5.71 |
| 82570 | <1% | 83 | $4.63 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,047 | $3.88 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 676 | $1.44 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 19 | $0.00 |
| 83550 | 0% | 39 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 16 | $0.00 |
| 97535 | Self-care/home management training, each 15 minutes | 0% | 283 | $0.00 |
| 97162 | 0% | 81 | $0.00 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 0% | 264 | $0.00 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 0% | 561 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 33 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 112 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 32 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 109 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 528 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 28 | $0.00 |
| 88342 | 0% | 12 | $0.00 | |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 31 | $0.00 |
| 85018 | 0% | 17 | $0.00 | |
| 64493 | 0% | 20 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 20 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 14 | $0.00 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 14 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 17 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 14 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 16 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 15 | $0.00 |
| 83615 | 0% | 12 | $0.00 | |
| 64494 | 0% | 30 | $0.00 | |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 14 | $0.00 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 210 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 94 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 637 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 151 | $0.00 |
| 82248 | 0% | 16 | $0.00 | |
| 87209 | 0% | 37 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 28 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 36 | $0.00 |
| 82010 | 0% | 28 | $0.00 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 197 | $0.00 |
| A6203 | Composite dressing, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | 0% | 26 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 26 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 36 | $0.00 |
| 93976 | 0% | 12 | $0.00 | |
| 83540 | 0% | 41 | $0.00 | |
| 87076 | 0% | 15 | $0.00 | |
| 64495 | 0% | 27 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 32 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHERRON, MICHAEL (CFO)
| Provider | Location | Paid |
|---|---|---|
| Methodist Healthcare System of San Antonio, LTD., L.L.P. | San Antonio, TX | $68.01M |
| Bay Medical, LLC | Chesapeake Beach, MD | $922K |
| Sugar Mill Diagnostic Imaging LLC | Homosassa, FL | $170.68 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.